How we work with healthcare companies

Healthcare companies (including pharmaceutical, medical technology and diagnostic companies) have a crucial role to play in improving diagnosis and treatment options for people living with IBD.

The IBD Registry receives support from commercial companies in a number of ways, including funding for studies, sponsorship and grants that can benefit IBD hospital teams and patients.

When working with industry, we follow clear guidelines to ensure openness, independence, transparency and impartiality. These are listed below:

  • We will only enter partnerships that align with our mission to improve the lives of people with IBD and do not compromise our independent status.
  • All studies that receive financial support from the pharmaceutical industry will be governed by the IBD Registry, approved by our Patient Advisory Group and led by principal investigators approved by the IBD Registry’s research committee.
  • We will work with a variety of companies in order to share knowledge and expertise for the benefit of people with IBD. We will not give preference to any one company in particular.
  • We will not align the IBD Registry brand with the promotion of a specific product. We will not directly endorse any commercial third party, its products or services.
  • Partnerships must comply with relevant codes including the ABPI Code of Practice for the pharmaceutical industry (or appropriate equivalent) .
  • We will work within the industry principles set out by the Association of Medical Research Charities (AMRC).
  • Under these principles we were pleased to launch the Industry Working group (IWG) in 2016. The IWG helps to provide the IBD Registry with specific expertise and industry engagement within a transparent framework.

You can read our full Statement of Working with Industry here.

You can also see a list of our industry supporters here.